Patterns of Late Gadolinium Enhancement in Chronic Hemodialysis Patients

JACC: Cardiovascular Imaging

Volumn 1, Issue 4, 2008, Pages 450-456

  Schietinger, Brian J ^a   Brammer, Glenn M ^a   Wang, Hongkun ^a   Christopher, John M ^a   Kwon, Katherine W ^a   Mangrum, Amy J ^a   Mangrum, J Michael ^a   Kramer, Christopher M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

gadolinium; hemodialysis; magnetic resonance imaging

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; IMAGE ANALYSIS; KIDNEY FAILURE; KIDNEY FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 47349110670     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.03.011     Document Type: Article

References (35)

1. U.S. Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2006), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. Robin J., Weinberg K., Tiongson J., et al. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. Heart Rhythm 3 (2006) 1196-1201
3. Levey A.S., Beto J.A., Coronado B.E., et al., on behalf of National Kidney Foundation Task Force on Cardiovascular Disease. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis 32 (1998) 853-906
4. Parfrey P.S., Foley R.N., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11 (1996) 1277-1285
5. Food and Drug Administration. Public Health Advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance (December 22, 2006)
6. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
7. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
8. Myerson S.G., Bellenger N.G., and Pennell D.J. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 39 (2002) 750-755
9. Stewart G.A., Foster J., Cowan M., et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 56 (1999) 2248-2253
10. Hunold P., Vogt F.M., Heemann U.W., Zimmermann U., and Barkhausen J. Myocardial mass and volume measurement of hypertrophic left ventricles by MRI-study in dialysis patients examined before and after dialysis. J Cardiovasc Magn Reson 5 (2003) 553-561
11. Isbell D.C., and Kramer C.M. Cardiovascular magnetic resonance: structure, function, perfusion, and viability. J Nucl Cardiol 12 (2005) 324-336
12. Mahrholdt H., Wagner A., Judd R.M., Sechtem U., and Kim R.J. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26 (2005) 1461-1474
13. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., and Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
14. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1977-1985
15. Bello D., Fieno D.S., Kim R.J., et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 45 (2005) 1104-1108
16. Kwong R.Y., Chan A.K., Brown K.A., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113 (2006) 2733-2743
17. Fieno D.S., Hillenbrand H.B., Rehwald W.G., et al. Infarct resorption, compensatory hypertrophy, and differing patterns of ventricular remodeling following myocardial infarctions of varying size. J Am Coll Cardiol 43 (2004) 2124-2131
18. Mahrholdt H., Wagner A., Holly T.A., et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 106 (2002) 2322-2327
19. Cerqueira M.D., Weissman N.J., Dilsizian V., et al. on behalf of Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002) 539-542
20. Crowder M., and Hand D. Analysis of repeated measures (1990), Chapman and Hall, Boca Raton, FL
21. Alfakih K., Plein S., Thiele H., Jones T., Ridgway J.P., and Sivananthan M.U. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 17 (2003) 323-329
22. Wu E., Judd R.M., Vargas J.D., Klocke F.J., Bonow R.O., and Kim R.J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 (2001) 21-28
23. Mahrholdt H., Goedecke C., Wagner A., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109 (2004) 1250-1258
24. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 128 (2005) 1629-1637
25. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 (2003) 54-59
26. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
27. Mark P.B., Johnston N., Groenning B.A., et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69 (2006) 1839-1845
28. Cooper M.E. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17 (2004) S31-S38
29. Mall G., Huther W., Schneider J., Lundin P., and Ritz E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5 (1990) 39-44
30. Maceira A.M., Joshi J., Prasad S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005) 186-193
31. Gejyo F., Odani S., Yamada T., et al. Beta 2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30 (1986) 385-390
32. Floege J., and Koch K.M. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes. Clin Nephrol 42 Suppl 1 (1994) S52-S56
33. Amann K., Rychlik I., Miltenberger-Milteny G., and Ritz E. Left ventricular hypertrophy in renal failure. Kidney Int Suppl 68 (1998) S78-S85
34. Silberberg J.S., Barre P.E., Prichard S.S., and Sniderman A.D. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36 (1989) 286-290
35. Zoccali C., Benedetto F.A., Mallamaci F., et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65 (2004) 1492-1498